This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk10: Greetings and welcome to the Aurora Cannabis Third Quarter 2024 Results Conference Call. All participants will be in a listen-only mode and a question and answer session will follow the formal presentation. This conference call is being recorded today, Thursday, February 8, 2024. I would now like to turn the conference over to your host, Anant Krishna, Vice President, Corporate Development and Strategy. Please go ahead.
spk12: Thank you, Operator. Hello everyone and thank you for joining us today. On the line with me are Miguel Martin, CEO, and Glenn Ibbett, CFO. This morning, Aurora issued a news release announcing our fiscal 2024 Third Quarter financial results and a separate news release announcing the acquisition of Med Relief Australia. These separate news releases and our fiscal Q3 2024 financial statements and MD&A are available on our IR website and can also be accessed by CDAR Plus and Edgard. In addition, you will find a supplemental information deck on our IR website. Listeners are reminded that certain matters on today's conference call could constitute forward-looking statements that are subject to risks and uncertainties related to our future financial or business performance. Actual results could differ materially from those anticipated in these forward-looking statements. The risk factors that may affect actual results are detailed in our annual information form and other periodic filings and registration statements. These documents may similarly be accessed via CDAR Plus and Edgard. Following prepared remarks by Miguel and Glenn, we will conduct a question and answer session with our covering analysts. With that, I will turn the call over now to Miguel. Please go ahead.
spk05: Thank you, Anant. Our quarterly performance demonstrated not only the strength of Aurora's business model, built primarily upon global leadership and high margin medical cannabis, but also our financial discipline. Our highlights include, first, strong revenue of over $64 million, have several percentage points, inclusive of 41 percent growth in our international medical cannabis segment. Second, industry-leading adjusted gross margin of 50 percent, also up from the year-end period. Third, a record adjusted EBITDA, representing our fifth consecutive quarter of positive adjusted EBITDA. Fourth, recall that we have also one of the strongest balance sheets of any Canadian LP, and our global cannabis business will be debt-free later this month. All of these items move us closer towards our goal of generating positive pre-cash flow in calendar 2024. But before delving into Q3 into greater detail, I first wanted to review our announcement today regarding the acquisition of the remaining 90 percent equity interest in MedRelief Australia that Aurora does not currently own. They are a leading distributor of medical cannabis products in Australia. The company was acquired at a total enterprise value of $44 million Canadian dollars, of which $8.3 million Canadian dollars was paid in cash, and the remainder satisfied by the issuance of Aurora shares. This transaction was thoughtfully structured to preserve the strength of Aurora's balance sheet and represents a strategic milestone in Aurora's global cannabis leadership, as we have now become the largest platform in the nationally legal cannabis industry in the world. Acquiring MedRelief Australia positions us to deliver double-digit increases to the profitability of our Australian business model through higher revenue contributions and higher gross margins. It further aligns this business with our other key profitable international markets, most notably Germany, Poland, and the UK. It is immediately accretive to our adjusted EBITDA and accelerates our path to positive cash flow generation before the end of the calendar year. We first partnered with MedRelief Australia back in 2017, and since that time we have been an active contributor to its growth by leveraging our pharmaceutical-grade cultivation and science-driven approach to product innovation. Like Germany, the Australian market is characterized by a clinician-led, traditional pharma-like product distribution model that closely aligns with Aurora's operational success. The high regulatory standards of the Therapeutic Goods Authority makes Australia a challenging market for new entrants, while providing an advantage to companies like Aurora who are able to meet them. MedRelief Australia already holds the number two position in medical cannabis in Australia, having already invested in clinician education while leveraging Aurora's comprehensive product portfolio to provide -in-class medicine and support for this rapidly growing patient base. We are extremely excited about our opportunity within the rapidly growing $400 million Australian dollar market. This would make it the largest medical market in the world outside of North America. We welcome MedRelief Australia fully into the Aurora fold and know that we will be able to do great things together. Now let's look more deeply into our business. In Canada, we maintained our number one position in the medical market and continue to grow our market share through our broad and attractive product assortment, positive sales mix, and most importantly product innovation. Amid a continuous disruption in this market, we know that our commitment to launching a steady stream of exciting new products is critical to holding and growing our domestic medical share. Our next generation cultivars can and often are made available across Europe and Australia, providing patients with some of the highest potency and most appealing offerings in these international markets. Of course, our ability to offer pharma-grade products to global patients is only made possible by our competitive advantage of having built a production network of indoor EUGMP certified facilities that are managed by teams who have deep experience in pharmaceutical production. As we already discussed, Australia earlier was now delving into our European operations as we generated sales in a record seven European countries, Germany, Poland, the UK, France, Switzerland, Malta, and the Czech Republic. In Germany, our largest European market where we've been operating since 2017, we're one of only three companies with a domestic production facility. We have the number two market share for flowers according to the latest data and the number one market share for self-payers. We also had three of the top ten cultivars in the country by volume sales. We are supportive of the legislative process that is moving towards the descheduling of medical cannabis and the potential wider legalization of adult use cannabis. We are very supportive of this effort and uniquely well positioned to benefit as the number one supplier of flower to patients outside of the public insurance system. In Poland, our second largest European market, Aurora earned the number two cultivar and the number two market position by volume. We are excited about the opportunities that this growing market presents. In the UK, patients are responding favorably to the launches of our next generation cultivars, which has led to significant increase in sales in Q3 compared to Q2. In Switzerland, we are building on a successful launch in Q2, becoming a trusted favorite for patients and are currently widening distribution channels in the country. All in all, medical cannabis adjusted gross margin remains strong at 62% as we benefit from sustainable cost reductions and improved efficiency in production operations. Turning back to Canada, our decision to strategically allocate product to higher margin medical markets resulted in a modest and expected -over-year revenue decline in the consumer cannabis business. Still, our adjusted gross margin improved substantially versus the year ago period because of our higher efficiency in production operations and a more favorable product mix. Finally, we exhibited the inherent benefits of a diversified model as we are expanding our reach in the controlled environment agricultural industry through Bevo. Their team is currently leveraging our cannabis facilities to move into the profitable cultivated orchids market, while their current vegetable and plant propagation business already generates a steady, predictable financial performance, albeit on a seasonal cadence. In the upcoming two to three years, we think that our shareholders are benefiting from the value creation coming from this segment as we expect the acceleration of Bevo's business plan to continue to drive revenue and ebota growth. All of our strategic progress over the past few years will move us towards our goal of positive pre-cash flow in calendar 2024. With that, I would now like to turn the
spk01: call over to Glenn for a detailed financial overview. Thank you, Miguel,
spk07: and good morning, everyone. Q3 is representative of our success in executing our business transformation and the tangible and positive results it has brought to our company. Our cash balance was over $200 million as of quarter close, and later this month, we will repay the remaining convertible senior notes with cash, approximately $7.3 million Canadian dollars. And that completes the repayment of nearly $540 million of debt over the last three years, and will leave our cannabis business debt-free. Now looking to Q3, big picture, we delivered revenue growth of .5% over the comparable year-go period, including a significant increase in sales from our high margin global medical cannabis segment. On profitability, consolidated adjusted gross margin rose to 50%, and adjusted EBITDA rose to a record $4.3 million, reflecting a $1.4 million improvement from last year and our highest quarterly result for adjusted EBITDA yet. Q3 also marked our fifth consecutive quarter of positive adjusted EBITDA. Now let's go into greater depth on our results. In Q3, net revenue rose to $64.4 million, up $3.3 million from $61.1 million in the year-go period. Overall, medical cannabis generated $45.1 million of net revenue, up $6.2 million compared to last year. By segment, international medical revenue was $19.3 million, up 41% from last year, and Canadian medical cannabis was $25.8 million, up .3% -over-year. Our performance in our medical channels was largely due to the positive market reaction to our Canadian-grown high-potency cultivars in key European markets, and to the continued rapid growth of the Australian medical market. Adjusted gross margin for medical cannabis was 62% in Q3, down 1% versus the year-go period. The consistently high margin is the result of sustainable cost reductions and improved efficiency in our production operations, with our shift to supplying Europe from Canada as the impact of closing our Nordic production facility begins to flow through our financials. As usual, driven by our focus and leadership in global medical markets, medical cannabis represented about 90% of our total cannabis adjusted gross profit dollars, and increased 15% to $28 million in Q3 compared to $24.4 million in the year-go period. Consumer cannabis net revenue was $11.6 million, down from $14.6 million the year-go. The change was the expected result of our decision to reallocate product to the higher margin markets. Adjusted gross margin for consumer cannabis was 26% compared to 20% in the prior year period. This significant increase in margins is coming from higher cultivar yields and continued efficiency improvements in production that are driving lower unit costs. In plant propagation, revenue of $7.3 million grew 10% from $6.6 million in the year-go period.
spk00: You will
spk07: recall that the seasonality of this business delivers higher revenue in the late winter and spring months, which should result in about 65 to 75% of revenue and up to 80% of EBITDA in the first half of the calendar year, so our fiscal Q4 and Q1 periods. Plant propagation adjusted gross margins were 18%, up from 15% in the year-go period. The increase was due to product mix between vegetable and ornamental plant sales. Our consolidated adjusted SG&A was well controlled at approximately $27.5 million and continues to reflect our ongoing commitment to keeping SG&A below $30 million in the current business. Turning now to cash flow, we made significant progress in Q3 towards our goal of positive cash flow in calendar year 2024 and remained firmly on track to achieve that goal as our operations used only $5.3 million in the quarter inclusive of work and capital investment. This is down sequentially from $30.9 million and considerably down from the $60.6 million use in the year-go period. As planned, our target of $40 million in annualized expense reduction is being realized mainly in Q3 and Q4. This is driven by the continued operational efficiency initiatives, including the shutdown of our Nordic production site and the sale of our Dutch assets, with the remaining expense reductions flowing through in Q4. As we manage working capital during the company's shift forward into growth opportunities, we have been successful in balancing the working capital needs of both investing in growth and executing disciplined financial management. For CapEx, we invested approximately $2.8 million this quarter, split evenly between maintenance and growth initiatives. Now looking forward to our next quarter, fiscal Q4 2024. Canadian medical and consumer segments are expected to be steady quarter over quarter, while Europe and Australia should both provide growth in their regions. The acquisition of MedRelief Australia should provide both incremental revenue for each gram of cannabis sold and deliver the commensurate improvement in gross margins in that region. By Q1 of our next fiscal year, we expect all three of our global medical regions, Canada, Europe, and Australia, to be delivering adjusted gross margins that exceed our target of 60%. For plant propagation, we expect to see seasonally higher revenues and gross profit that would be in line with historical performance in the comparable prior year period. So revenue growth combined with ongoing cost control are expected to result in continued positive adjusted EBITDA in Q4 2024. To wrap up, our strengthened financial condition is due entirely to the commitment to operational excellence and strategic focus of our team. We are positioning our diversified global cannabis business to deliver dependable revenue growth over the long term. Thanks very much for your interest. I'll now turn the call back to Miguel.
spk01: Thanks, Glenn. If there's one takeaway for our investors,
spk05: it would be that strategically and financially, we were in the best shape ever. This is all thanks to our team accomplishing, accomplishing what we set out for them to do. We fully intend to make good on our commitments for top line growth and continued and sustainable adjusted EBITDA generation. $200 million of cash on hand, we're in a strong position as we work towards our goal of generating positive pre-cash flow this
spk01: calendar year. Operator, please open the lines for questions.
spk10: Thank you. We will now be conducting a question and answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. Today, participants will be permitted one question and one follow-up question, after which analysts will need to re-queue. One moment please while we poll for questions. Our first question comes from Frederico Gomez from ATB Capital Markets. Please proceed.
spk08: Hi, good morning. Thank you for taking my questions. My first question is on your acquisition in Australia. You mentioned it's a market worth about $400 million, Australian dollars, and that it's rapidly growing. Can you give us an idea of how fast that market is growing? What are the drivers behind that growth? As well as what sort of assets you have in place there with that acquisition and the opportunity Australia represents? Thank you.
spk05: Good morning, Fred. We are incredibly excited about this acquisition. As I said in my comments, this is a business that we've been partnered with since 2017. We own 10% of it. Great operators, ex-monitors, wonderful piece of business there. First and foremost, the $400 million a year of Australian revenue market sizing is coming from a report published by the Pennington Institute. They really leveraged the number of units sold represented by, reported by the TGA, which is the key regulatory unit. Then they multiply that by an average selling price per unit. Listen, it's not Nielsen or IRI, but that's the key piece of it. The TGA is the primary regulatory body in Australia. They're the ones who publish the units sold on a six-month basis. Just in terms of growth, if you look back to 2022, the market size was estimated to be about 234 million Australian. That grew in the first six months and we've seen steady growth. The number of approvals, which is a key indicator on prescriptions, also continues to grow. In the first half of 2023, we saw close to 320,000 new approvals. This represents a significant increase since July of 2016. When you compare that to say Canada, where we've seen some improvement, it's a significant growth. That's that piece. The company that we're buying is number two in the market. That market data comes from a different data source, which is called Nostradata, which is Australia's leading pharmacy data partner. It is important to know that it's a representative sample and not all pharmacies are signed up for it. We've had great success in this market on multiple brands and we're really excited about it. As I mentioned, the TGA has done a wonderful job being regulatory forward and science-based. We think this is a market that clearly advantages regulatory forward, TGA-approved suppliers, of which we are. We're thrilled about having a foothold and having such a great acquisition that will be margin
spk01: -cretive day one in that key market.
spk08: Thank you for that, Caller. My second question here is just about Germany. We have the vote there expected to happen soon. I'm just curious, how do you think that bill, if it passes, how do you think that could impact the medical market and the opportunities there in Germany? Thank you.
spk05: Yeah, I appreciate that. Germany is obviously a key market for us. As I said, we're one of three companies that have domestic production, which is a significant advantage. We're hopeful that we're going to hear something in late spring, particularly around the de-scheduling or the removal of cannabis with a narcotic designation. That in itself will have a massive impact to that market because it will allow both the pharmacists that prescribe it as well as the patients that have greater access to that product. Now, the actual timing and how this is going to manifest itself, we'll have to see in the regulations. We are very supportive, though, of these actions and have found that the German regulators, whether it's been the approval process, the testing process, the certification process, have all done a really good job with this and these things take time. But we think that that legislation is going to have a really significant impact for those companies like us that participate in the medical portion of that. And obviously, we'll have a tag-along impact as we see other markets around them, such as Poland, Czech Republic, France, and others look. So momentum builds momentum, particularly in that part of the world. And we're thrilled about that progress and looking forward to seeing the regulations when they come out.
spk01: Thank you very much. You're very welcome, Fred. Appreciate it.
spk09: Our next question
spk10: comes from Matt Bottomley from Canaccord. Please proceed.
spk02: Good morning, everyone. Thanks for the color so far. I just wanted to pivot back to more domestically in the Canadian medical side of things, not something that gets talked about a lot in general, just given that it's a pretty immaterial portion of most other LPs strategy at this point. So it seems like it's been at this 25 million a quarter, 100 million-dollar revenue business for some time. And I'm just wondering if you can maybe explain or give some more color on the dynamics of is the overall market TAM of medical slowly shrinking, given that retail is not hard to find, particularly in provinces like Ontario, and then just strategies maybe in order to increase that share, whether it's through other LPs kind of closing up shop or other strategic initiatives in order to get increased registrations into Aurora.
spk05: Well, Matt, good morning. And listen, it's a great question. I think there's two parts to that question. So let me take the question as you laid it out, and then I'll add a little color to it. So, yes, we believe that the roughly $400 million a year of Canadian revenue is declining slightly. We've been able to offset that by growing our market share. That being said, we do think there's opportunities to grow that pie. Now, the impact initially due to the growth of the rec business and the availability of rec products could have an impact. But because of the reimbursement aspect that you wouldn't get in a recreational environment, we see those patients that are in that system, particularly the veteran patients, getting great value and great service that they would not get in the rec business, mostly because of the renewable energy. Reimbursed model. And so there's that. Secondly, we do see an opportunity for that Canadian medical business to grow. We are seeing interest in unions and other sort of entities looking at cannabis as a benefit getting bigger. And I will mention that we're now starting to see more and more clinical trials and the traditional medical establishment doing work on cannabinoids that would open up. Today, it is only 1% of the Canadian adult population that is in the medical cannabis system. So there is plenty of opportunity. Now, the medical cannabis business is the highest margin portion of all cannabis globally. So it's an incredibly compelling piece. The other thing that's very important to understand is that having excellence in Canada, which is such a critical federal legal medical cannabis market allows you to learn and become adept at navigating other federally legal cannabis markets of which we're now the largest. And so, you know, our leadership that we have in Germany and Poland, you know, these key markets comes directly from what we've learned in Canada. And we are able to leverage similar products and similar executions because of the world class production in Canada and shipping those EUGMP products around the world. So I listen, we are thrilled about, you know, our leadership in the Canadian market and being a Canadian medical cannabis company. But clearly we get great advantages of out of leveraging that exact same system all around the world.
spk02: Great. Appreciate all that. Just one more for me on general sort of philosophy or strategy when you kind of look at a number of these international markets. I'm just wondering in terms of the timing of allocation and deployment of capital or M&A dollars into certain markets predicted in Europe. You know, what are some of the key things that maybe you look at? You had one of your U.S. counterparts earlier this week announce the deal into Poland. I know Poland is a market you guys have talked about a little bit. I think they had mentioned, you know, there's a huge amount of investment in leg time into getting products registered, which if you get in the market now, obviously can be a benefit in terms of first mover. But are there other things you look at it? Is it the scarcity of licenses, you know, just overall regulatory, you know, landscape with respect to how things are written up versus timing of when you expect maybe markets to launch? It's something that gets talked about a lot in this sector, but I think a lot of investors have been, you know, more or less, you know, have seen the can get kicked down the road with when markets outside of the U.S. and Canada actually have really started to gain acceleration.
spk05: Yeah, it's a great question. And I think it's one that, you know, we spend a lot of time on and I would argue that we're one of the best at. So we have pretty, you know, significant modeling work that's done on each of these markets. We also spend a significant amount of money in the local markets, having people in the local markets, particularly on the GRGA side. So I would tell you when you boil it down, the calculations really are based on three core segments. The first is our assessment of the regulatory environment. Is it going to be science based? Is it going to be EUGMP? What is the testing system going to be? What is the registration system going to be that you just mentioned? And what we found is that there are some markets like Germany, like Poland, like a lot of markets that we're in that are very rigorous in these processes. They're science based. They do their own testing. You know, it's very formal. Now, in some cases, it takes longer than people would like, but usually they do not go backwards. And so you can have predictability in terms of those investments. The second aspect would be, you know, the size of, you know, the opportunity. Is it going to be self-payer? Is it going to be reimbursed? What's the size of the population? What are the overall, you know, economics that allow us to make a, you know, thoughtful investment thesis about where we're going to go? And then third is how are we going to play that market? And we've demonstrated great flexibility, whereas in some markets we are both the manufacturer and the wholesaler and have a sales organization. And in other markets, we'll just be the manufacturer and partner with world class wholesalers and sales organizations. And so in all of that, I think, you know, we've done an excellent job. And as I mentioned, one of the benefits is you're seeing the same companies and particularly Aurora being successful in all of these markets. And unlike, say, Canada, usually the top five companies will account for two thirds or three quarters of the overall business in these European markets, whereas in Canada it might take you 20 or 30 companies. So the benefits are there. And as I said, the same execution and the same infrastructure, EOGMP products, you know, GR registration, all of the work that we do on the science side allows us to sell the same products in Poland, in Germany, in the UK and develop, you know, great efficiencies for us. So it's difficult. It's something that we spent a lot of time on, but it's definitely paid dividends for us, as you see from our results.
spk03: Okay, great. I'll get back into you and appreciate all the details on that. You got it. Thank you.
spk10: Our next question comes from Tammy Chen from BMO Capital Markets. Please proceed.
spk11: Oh, great. Thanks. First question is going back to Australia. So, Miguel, you talked about how the number of approvals continues to grow a significant increase compared to 2016. I just wanted to revisit this part. Like, what has really caused the Australian market to experience such rapid growth? Like, we see some other medical markets that, you know, legalized, but the growth just isn't as significant. Like, has there been some further regulatory changes over these last few years that have really increased or, yeah, increased the acceptance of medical cannabis amongst physicians there? I'm just curious what is driving this quite rapid growth?
spk05: Yeah, Tammy, it's a great question. I think, you know, I would tell you there's probably three key aspects to this. First is that the TGA, which is the primary regulatory agency, has done an exceptional job at, you know, rolling out regulations and having it be easier for all steps of the process. And so what do I mean by that? The process in which physicians and clinicians can sign up to be a prescribing physician, the ease in which pharmacies can be registered and be allowed to service the patients, the patient's ability to register through. So as I mentioned, it is a very large reimbursed market, so the economics works well. They have a compassionate care program for those that are economically challenged to have access to medical cannabis through that. So that would be the first part. The second part is they've also been very thoughtful at the local level. So there's, you know, sometimes there's tension between, you know, the federal legalization and what happens at the state level. We have not seen that in Australia. And so you've seen a very, you know, specific sort of cadence and move forward. And then I think third, you know, culturally cannabis, you know, has been accepted in this market. And I think that those companies that have operated there have done a really good job, which is why we've seen such consolidation in market share. The largest market share company in that market has over a 30 share. We're number two in the low 20s. And then there's, you know, one right below us. So all of that, I think, is, you know, come together to have this be now, you know, unlike some other markets we've seen. Because the TGA is being so rigorous with their authorizations and their review of acceptable products, we don't, you know, we think this will continue to be a market that advantages those companies that have, you know, that type of rigor to their production, to their certification. And, you know, this is all happening in the absence of other formats that we see, you know, being larger in other markets, particularly, you know, ingestibles and vapor products. And so those will be coming online and can only grow, you know, this overall market. So we're excited about it. It's a part of the world that, you know, this is sort of
spk01: an
spk05: important
spk01: piece. And we're really, really excited about this acquisition.
spk09: Great. That's helpful.
spk11: Well, sticking with that, I was curious to understand why now for timing of acquiring the rest of the stake in Med Relief Australia. Is it just, you know, you've seen the market experience tremendous growth and felt like now is the right time. And lastly, did you say that this business, Med Relief Australia, has a higher gross margin than your current international business? Thanks.
spk05: Yeah, so let me take the second one first and then I'll take the first one. So currently we are the supplier. We are the manufacturer for Med Relief Australia. They have their own sales organization. They have their own clinic connection organization. And so our margins were lower. So my statement was that upon acquisition, it would be similar from a margin standpoint to other markets that we have, say, in Western Europe or Eastern Europe, which are some of the highest margins. You see in cannabis globally, you know, as those margins today are in the low, low sixties in terms of why now, you know, I would say there are a couple of things. One is, as I talked to you about earlier, I mentioned earlier about our analysis about regulations, market size, and our ability to sort of leverage that. And we felt that we were in an inflection point because of the size of the market, because of where the regulations were, and because of our ability to leverage innovation in some of these new formats coming on. Clearly, you know, the other side, the owners of the business also had to be aligned that this was the right time. And, you know, I can only say great things about what they've done to build this business. Like I said, the founder is an ex-pharmacist, and that team has done just a superb job building this business. And we collectively thought this was the right time to take the next step. And, you know, with the products that we have online to be able to leverage in Australia, with the, you know, the cash position that we have and everything else going on, the collectively both, you know, Aurora management as well as the ownership of Metrolip Australia felt this was exactly the right time
spk01: for us to leverage. For us to, you know, make this, make this deal happen.
spk09: Okay, great. Thank you.
spk01: You're very welcome.
spk09: Our next question comes from
spk10: Doug Meeam from RBC Capital Markets. Please proceed.
spk06: Yeah, good morning. My question just has to do with capital allocation. When you look at the Australian acquisition and the amount of cash used versus shares issued, can you walk through the decision making process there and why you decided you needed so much dilution relative to the 10 million or so? You know, from the $8 million Canadian that you paid out, especially given that your balance sheet is so much better now and you're on the cusp of turning free cash flow positive. Thank you.
spk05: Sure, well, I'll make a couple comments and then allow Glenn to get there. I think you know, we are we've worked incredibly hard to take out, you know half a billion dollars in the convertible debt and Really want to demonstrate that the company is being incredibly thoughtful With the financial decisions that we make now that's not gonna come at the expense of growth. And so it was our opinion That that was the right allocation to use that amount of stock versus the amount of cash in order to retain maximum flexibility With that cash position and I think you know, I understand your point about dilution But I think from a shareholder standpoint if you look at that valuation and you look at their You know trailing 12-month revenue as of December 31st was about 40 million in Australian And the fact that it's a creative day one You know, we believe that is the was the right allocation, you know for this deal going forward But listen, yeah, I understand the question but all in all, you know If you look at where we are now free cash will pause it by the end of the year You know roughly two hundred million dollars in cash on hand no debt on the cannabis business And now with this piece coming online which may be as large as Canada Which would make it the largest federal illegal medical Candice market in the world. We feel really good about it And you know, and that was the structure of the deal but glad anything you want to add to the the allocation there?
spk07: No, it's pretty thorough Miguel Doug I will note you know, we've been very consistent in our messaging over the last couple years that The share issuance we've really tried to refocus that on Incremental creative new business, you know, so it's strategic focus as opposed to you know, you know back A number of years ago a number of cannabis companies used it to fund operations. So this is not about funding operations This is about adding, you know that incremental revenue and margin that Miguel's talked about very creative The value is quite compelling So all the strategic reasons that Miguel laid out But we see shares as a valuable tool when we are looking at it strategically So that's you know, it was part of the thinking on this as well Consistent with what we've told you in the market over the last couple years of what we've reserved our shares for
spk06: Okay That's helpful. And then just maybe as a follow-up there Given that this group is going to be reasonable size shareholder of the company would you expect them to be? long-term shareholders of the company
spk01: I Don't know I mean that's going to be up
spk05: to the up to the shareholders of it We would hope you know, everybody would be a long-term shareholders of this company, but that's their decision and and you know I think is not You know doesn't have any bearing in terms of how we run the company of the deal or anything going forward
spk01: Okay, great. Thank you. You got it. Thank you
spk09: Our next question
spk10: comes from Pablo Zuanek from Zuanek and associates, please proceed
spk04: Good morning, everyone Miguel, you know just thinking about the potential acquisitions you need to make in Germany, you know following what you did in Australia Maybe explain the difference of your On the ground business model in the case of Australia you were shipping from from Canada, right? I'm pretty much the medical if Australia was taking care of everything else in the case of Germany It seems to me that you have more assets on the ground more feet on the ground But you know once we have a change in the narcotics law and other changes Do you think you will need to make acquisitions in Germany or pretty much is about investing on what you have already?
spk01: Thanks Yeah, I mean, you know Bob I think
spk05: For
spk01: Australia we found such
spk05: a great partner That we were comfortable with not you know Going all the way through now, obviously it impacted the margin when you're just a manufacturer That's the trigger to buy the rest of it so that we could you know experience the same margins that we see in other parts of the world Germany was different and And obviously, you know that you've been covering this for us Very early on again to go back to those three criteria We got very comfortable with the regulators and the regulatory process We got very comfortable with the size of the market and the fact that it was going to be a reimbursed Market with also a large self-payer and we also got comfortable with the unique proposition that they offered there to have in-country manufacturing and Be aligned with the government and her first mover status it was for that reason that you're right that we have quite a significant amount of headcount and infrastructure both in Berlin Where we have sales marketing finance back office and very importantly government relations Work there as well as the production team that we have at Moina and I think you know that shows Our flexibility and you know if you go east and you look at a country like Poland, we've got sales and marketing In Poland, but we don't do any production in Poland because we can bring product in at a very efficient way with our new genetics Coming in from Canada. If you look at say a market, you know, like that like the Czech Republic We work with partners same thing we do in Switzerland and with Austria And so I think you have to be flexible but at the core You have to have the products that patients and clinicians want and we're able to do that Incredibly efficiently out of Canada, but as markets, you know get there We're gonna continue to make investments and we're thrilled to have that, you know opportunity now to be completely integrated You know in Australia, which will look a lot like we have, you know in Germany
spk04: right and just a quick follow-up in the case of Australia, so They don't have production there. You're the company you acquire. Is that something you would look at down the road? You know, especially when you see the gifts of Israel, you know with a dumping claims and the market in Israel shutting down every now And then is that a risk in Australia? Would you need to have local production there? And if you're gonna expand on the argument you made about barriers to entry in Australia to other players?
spk05: Thanks, sure the opportunity just on on Israel. We haven't shipped to Israel in a year but you know, we are not You know, we've had production as you well know in other parts of the world and what we have found which is really important is that in all of these environments they allow for the importation of Registered or certified product in most cases. That's EUGMP in Australia they've been very thoughtful. They have their own registration process and certification process And we've worked with them on that and so because the economics and the efficiencies Of being able to do that in a centralized place like Canada Which is such an incredible place for us to grow we can leverage the same genetics the same process at very low energy costs And production costs and ship it around the world That's a significant advantage for us and we've not heard anything in Australia or none of those markets That would restrict the ability of Canadian grown EUGMP or TGA authorized flower to come into those markets now if we found something locally In any market we've got you know a long history of managing a variety of different facilities. And so we definitely Could do that, but we had not seen that in Australia now in terms of you know, your point about Restrictions the TGA the primary regulatory, you know authority in Australia is incredibly rigorous in What you know they allow so first and foremost the registration process is very rigorous and their requirements Are consistent with what we see in Europe but take anywhere between you know Eight and twelve months for every new product to be brought in and they review that they do their own testing Which they're reviewing the actual, you know, coas or certificates of assurance for all of these key products So you have to have you know vigilance and precision in your in your production They review every aspect of the labeling and the packaging as well as have certification For wholesale delivery and the pharmacies. It's a high bar Which is why you see, you know concentration and I don't think you're gonna see you know Actions in Australia that maybe you've seen in other markets And for that reason you see good margins. And so we're excited about that. We love working with the TGA And like I said, you know people can get a little frustrated about the pace sometimes of progress But when you have great markets like Australia or Germany or others They don't go backwards and that's very important from an asset allocation And I think that's why we're so excited about it and I think why we do
spk01: so well there
spk04: Right. Thank you
spk01: very welcome problem
spk10: This concludes our question and answer session I would like to turn the floor back over to Miguel Martin for closing comments
spk05: Well, first and foremost we thank everybody for your interest in Aurora We are so excited about where we are and as I said earlier, we've never been in better shape You know today was a great day to announce the progress that we've made in the core business But as importantly announced the acquisition of a great asset in one of the fastest growing and largest Medical cannabis markets in the world. We continue to believe Medical cannabis is the best place to be in cannabis globally and we've demonstrated our leadership there So we thank everybody again,
spk01: and we look forward to speaking to you soon. All the best. Bye
spk10: This concludes today's color teleconference you may disconnect your lines at this time Thank you for your participation
Disclaimer